

Bioprocess Validation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

<https://marketpublishers.com/r/B2C7C630076FEN.html>

Date: November 2024

Pages: 135

Price: US\$ 4,850.00 (Single User License)

ID: B2C7C630076FEN

Abstracts

The Global Bioprocess Validation Market reached USD 416.5 million in 2023 and is anticipated to grow at 10.7% CAGR from 2024 to 2032. Bioprocess validation plays a critical role in biopharmaceutical manufacturing, ensuring that processes consistently deliver products of high quality and safety. It involves systematic tests and analyses to verify that every stage, from raw material usage to final product output, meets strict regulatory and quality requirements.

The market expansion is largely driven by stringent regulatory demands, rising adoption of biologics, and advancements in validation technologies. As the biopharmaceutical sector grows, both in production capacity and outsourcing, there is an increasing need for comprehensive validation protocols to maintain compliance and uphold product standards. The surging demand for biologics, including monoclonal antibodies, vaccines, and gene therapies, further amplifies the necessity for robust validation processes, as these therapies must meet exacting standards for quality, safety, and efficacy.

Segmented by testing types, the market encompasses areas such as extractables and leachables testing, microbiological testing, integrity testing, and viral clearance testing, among others. In 2023, microbiological testing emerged as a dominant segment, generating USD 126.2 million in revenue. Regulatory bodies emphasize the importance of microbiological testing in ensuring sterility and quality throughout the manufacturing process. Adherence to Good Manufacturing Practices (GMP) and routine environmental monitoring are critical to safeguarding the integrity of biopharmaceutical products, underscoring the significance of this testing category.

By stage, the bioprocess validation market is categorized into process design, process qualification, and continued process verification. Process qualification accounted for the largest share in 2023, representing 46.8% of the market. This stage is essential in confirming that manufacturing processes consistently produce products within established parameters. By simulating real operating conditions, process qualification ensures the reliability and reproducibility of biomanufacturing protocols, bridging process design, and ongoing verification phases.

U.S. market reached USD 174.5 million in 2023 and is projected to grow at a CAGR of 10.8% during the forecast period. The regulatory landscape in the U.S. mandates rigorous validation practices driven by agencies such as the FDA. Compliance with GMP standards necessitates thorough validation of all manufacturing stages, prompting increased investments in innovative validation techniques.

The growing biopharmaceutical industry, coupled with regulatory pressures and the rising prevalence of biologics, positions bioprocess validation as a cornerstone of modern healthcare manufacturing.

Contents

Report Content

CHAPTER 1 METHODOLOGY & SCOPE

- 1.1 Market scope & definitions
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° synopsis

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Stringent regulations regarding safety and quality
 - 3.2.1.2 Increasing demand for biopharmaceuticals
 - 3.2.1.3 Rising R&D expenditure in life sciences sector
 - 3.2.1.4 Increasing demand for bioprocess validation outsourcing
 - 3.2.2 Industry pitfalls & challenges
 - 3.2.2.1 Complexity and time-intensive nature of validation
 - 3.2.2.2 High costs associated with validation processes
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Future market trends
- 3.7 Gap analysis

3.8 Porter's analysis

3.9 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2023

4.1 Introduction

4.2 Company market share analysis

4.3 Company matrix analysis

4.4 Competitive analysis of major market players

4.5 Competitive positioning matrix

4.6 Strategy dashboard

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY TESTING TYPE, 2021 – 2032 (\$ MN)

5.1 Key trends

5.2 Extractables/leachables testing

5.3 Microbiological testing

5.4 Integrity testing

5.5 Viral clearance testing

5.6 Adventitious agent testing

5.7 Mycoplasma testing

5.8 Physicochemical testing

5.9 Compatibility testing

5.10 Other testing types

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY STAGE, 2021 – 2032 (\$ MN)

6.1 Key trends

6.2 Process design

6.3 Process qualification

6.4 Continued process verification

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY MODE, 2021 – 2032 (\$ MN)

7.1 Key trends

7.2 In-house

7.3 Outsourced

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 (\$ MN)

8.1 Key trends

8.2 Biopharmaceuticals

8.3 Gene and cell therapy

8.4 Vaccines

8.5 Other applications

CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY END USE, 2021 – 2032 (\$ MN)

9.1 Key trends

9.2 Pharmaceutical companies

9.3 Biotechnology companies

9.4 CROs and CDMOs

9.5 Academic and research institutes

CHAPTER 10 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 (\$ MN)

10.1 Key trends

10.2 North America

10.2.1 U.S.

10.2.2 Canada

10.3 Europe

10.3.1 Germany

10.3.2 UK

10.3.3 France

10.3.4 Spain

10.3.5 Italy

10.3.6 Netherlands

10.4 Asia Pacific

10.4.1 China

10.4.2 Japan

10.4.3 India

10.4.4 Australia

- 10.4.5 South Korea
- 10.5 Latin America
 - 10.5.1 Brazil
 - 10.5.2 Mexico
 - 10.5.3 Argentina
- 10.6 Middle East and Africa
 - 10.6.1 South Africa
 - 10.6.2 Saudi Arabia
 - 10.6.3 UAE

CHAPTER 11 COMPANY PROFILES

- 11.1 Asahi Kasei Corporation
- 11.2 Bio-Rad Laboratories
- 11.3 Charles River Laboratories
- 11.4 Danaher Corporation
- 11.5 Eurofins Scientific
- 11.6 Lonza Group
- 11.7 Meissner Filtration Products
- 11.8 Merck KGaA
- 11.9 Pace Analytical Services
- 11.10 Repligen Corporation
- 11.11 Sartorius AG
- 11.12 SGS S.A.
- 11.13 Thermo Fisher Scientific
- 11.14 Tosoh Corporation
- 11.15 WuXi AppTec

I would like to order

Product name: Bioprocess Validation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

Product link: <https://marketpublishers.com/r/B2C7C630076FEN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B2C7C630076FEN.html>